image credit- shutterstock
South Korea-based Lunit, a leading provider of AI for cancer diagnostics and precision oncology, has announced a collaboration with Japanese pharma firm Daiichi Sankyo that aims to accelerate biomarker discovery and optimise translational research by integrating multiple AI-powered Lunit SCOPE digital pathology products across two oncology pipeline programmes.
Daiichi Sankyo will apply various Lunit SCOPE solutions, including SCOPE uIHC for quantitative IHC analysis and SCOPE IO for immune phenotyping and spatial analysis, to explore novel biomarkers and to potentially enrich clinical trials or to potentially support precision patient stratification for select oncology pipeline programmes.
"Lunit SCOPE was built to unlock hidden insights from pathology slides - quantifying the tumor microenvironment, predicting molecular profiles and generating data-rich features to inform trial design," said Brandon Suh, CEO of Lunit. "SCOPE uIHC is now enabling the next generation of IHC-based biomarkers. By working with Daiichi Sankyo, we are embedding these capabilities into translational and clinical research, enabling faster biomarker discovery and more precise patient stratification. Ultimately, this means more efficient trials and better outcomes, where each patient has a greater chance of receiving the therapy that works best for them."
The work will include exploratory research projects and analyses across two oncology assets across multiple types of cancer, with the potential to inform future trial designs, biomarker strategies and clinical development plans.
